Skip to main navigation Skip to search Skip to main content

National survey of invasive pneumococcal diseases in Taiwan under partial PCV7 vaccination in 2007: Emergence of serotype 19A with high invasive potential

  • Yu-chia Hsieh
  • , Pen Yi Lin
  • , Cherng-Hsun Chiu
  • , Yhu-Chering Huang
  • , Kuang Yi Chang
  • , Chun Hsing Liao
  • , Nan Chang Chiu
  • , Yin Ching Chuang
  • , Po Yen Chen
  • , Shan Chwen Chang
  • , Jien-Wei Liu
  • , Muh Yong Yen
  • , Jen Hsien Wang
  • , Cheng Yi Liu
  • , Tzou Yien Lin*
  • *Corresponding author for this work
  • Chang Gung Memorial Hospital
  • National Taiwan University
  • Veterans General Hospital-Taipei
  • Far Eastern Memorial Hospital
  • Mackay Memorial Hospital Taiwan
  • Chi-Mei Medical Center
  • Veterans General Hospital-Taichung Taiwan
  • Taipei City Hospital
  • China Medical University Taichung

Research output: Contribution to journalJournal Article peer-review

100 Scopus citations

Abstract

We conducted an active, population-based laboratory surveillance study to evaluate the epidemiologic features of invasive pneumococcal disease (IPD) in Taiwan. Concurrently, nasopharyngeal colonization of Streptococcus pneumoniae was evaluated among 1128 healthy children aged ≤5 years. The overall incidence was highest among children aged 2-4 years (15.6/100,000). Serotype 19A, which had never been reported in Taiwan previously, caused a substantial fraction of the invasive diseases (OR, 9.6; 95% CI, 3.1-29.4) among children aged 2-4 years. Comparing serotype distributions of the isolates from nasopharyngeal colonization among children aged ≤5 years, serotypes 14 (OR, 17.3; 95% CI, 5.2-57.9) and 19A (OR, 14.9; 95% CI, 1.9-117) had the highest invasive potential. The study found that serotype 19A expanded in Taiwan, a country with a low 7-valent conjugate pneumococcal vaccine coverage. The 7-valent conjugate pneumococcal vaccines covered 73% of cases in children aged between 2 and 4 years, and 64.7% of cases in children aged <2 years. Among patients aged ≥65 years, the 23-valent pneumococcal polysaccharide vaccine covered 70.4% of cases. In the future, a broader pneumococcal vaccine is needed.

Original languageEnglish
Pages (from-to)5513-5518
Number of pages6
JournalVaccine
Volume27
Issue number40
DOIs
StatePublished - 04 09 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Invasive pneumococcal diseases
  • Invasive potential
  • Serotype 19A

Fingerprint

Dive into the research topics of 'National survey of invasive pneumococcal diseases in Taiwan under partial PCV7 vaccination in 2007: Emergence of serotype 19A with high invasive potential'. Together they form a unique fingerprint.

Cite this